MSD Korea's osteoporosis treatment Fosamax, and Otsuka Pharmaceutical's antiplatelet drug Pletaal OD Tab will be withdrawn from the Korean market due to poor performance.

According to the MFDS on the 9th, as of the 8th, MSD Korea's Fosamax 10mg (Alendronic acid), Otsuka's Pletaal OD Tab 100mg, Pletaal OD Tab 50mg, and Pletaal Powder 20% (Cilostazol) have been withdrawn.

Fosamax, original for Alendronic acid, is a bisphosphonate-based osteoporosis treatment and is widely used in Korea. Pletaal, original for Cilostazol also has a high market share in Korea for antiplatelet drugs. These items are not flagship items.

Fosamax includes Fosamax 70mg, Fosamax PlusD, Fosamax Plus,